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estimate was based on prevalence data for URDs for which patented drugs are cur-
rently available and for which drugs are in clinical development and hence may 
be expected to be launched in the foreseeable future. A power function was used 
to estimate the relation between (decreasing) prevalence and (increasing) cost per 
patient. For drugs in development, we applied phase duration data and attrition 
rates from the Tufts Center for the Study of Drug Development database. Results: 
A total of 18 drugs under patent protection for non-oncological URDs were identi-
fied. Furthermore, 29 drugs for non-oncological URDs under development that have 
the potential of reaching the market by 2021 were found. Total budget impact over 10 
years was estimated to be € 14,112 and € 4,965 million for approved and pipeline URD 
drugs, respectively (total: € 19,077 million). Relative to total pharmaceutical expendi-
tures in Europe, spending on drugs for URDs is estimated to rise from 0.7% at present 
to 1.6% in 2021. Univariate sensitivity analyses and extreme scenario analyses sug-
gesting robustness of this projection will be presented. ConClusions: Our analysis 
does not support concerns regarding an uncontrolled growth in expenditures for 
drugs for URDs. Nevertheless, continuous monitoring of the budget impact as an 
input to rational policy making is recommended.
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objeCtives: The relatively low budget impact of orphan drugs is often used as 
an argument in reimbursement decisions. However, overall, the budget impact of 
orphan drugs can still be substantial. In this study, we assess the uptake and budget 
impact of orphan drugs in the Netherlands. Methods: We examined the number 
of orphan drugs, the number of patients and budget impact of orphan drugs in the 
Netherlands in the period 2006 to 2012, both for inpatient and outpatient orphan 
drugs. Budget impact was provided in absolute numbers and relative to total phar-
maceutical spending. Results: The number of orphan drugs and patients treated 
increased substantially over the period studied. Overall, budget impact increased 
substantially over a period of six years, both in absolute terms (426% increase) as 
well as relative to total pharmaceutical spending (378% increase). Growth rates 
decreased over time. In 2012, 17% of available drugs had an individual budget impact 
of more than € 10 million per year. ConClusions: Individual budget impact of 
orphan drugs is often limited, although exceptions exist. However, in total, the 
budget impact of orphan drugs is considerable and has grown substantially over 
the years. This could potentially influence reimbursement decisions for orphan 
drugs in the future.
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objeCtives: Biosimilar infliximab has been approved by EMA for the management 
of inflammatory autoimmune disorders including rheumatoid arthritis (RA), anky-
losing spondylitis (AS), Crohn’s disease, ulcerative colitis (UC), psoriatic arthritis 
(PsA), and psoriasis based on quality, safety and efficacy profiles comparable to inf-
liximab. The aim of this study was to evaluate the five-year budget impact of intro-
ducing biosimilar infliximab in the management of RA, AS, Crohn’s disease, UC, PsA, 
and psoriasis from the health care system perspective. Methods: An Excel-based 
budget impact model was developed. The numbers of patients eligible for infliximab 
were calculated based on disease prevalence rates in Germany, Italy, Belgium, the 
Netherlands and the United Kingdom. The price of biosimilar infliximab is not yet 
known; therefore three discount scenarios versus infliximab (10%, 20%, and 30%) 
were applied. Market share was assumed to be 25% in the first year in all scenarios. 
Annual market share growth was varied in each of the scenarios at 20%, 30% and 
40%, respectively. Results: The combined net budget savings for Germany, Italy, 
Belgium, the Netherlands and the United Kingdom in the first year were € 17.8, € 35.5 
and € 53.3 million for the 10%, 20% and 30% price discount scenarios, respectively. 
Over a 5 year period the net budget savings were € 132.8, € 322.8 and € 532.8 million 
for the 10%, 20% and 30% price discount scenarios, respectively. ConClusions: 
The introduction of biosimilar infliximab as a treatment option for patients with RA, 
AS, Crohn’s disease, UC, PsA, and psoriasis could achieve substantial cost savings 
for health care systems. In the price discount scenarios tested, the total combined 
savings across Germany, Italy, Belgium, the Netherlands and the United Kingdom 
over a 5 year period ranged from € 132.8 million to € 532.8 million. The net budget 
impact was highly sensitive to market uptake rates and the price discount applied.
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objeCtives: To estimate budget impact analysis (BIA) of belimumab plus stand-
ard of care (SoC) comparing the SoC alone in the treatment of patients suffering 
from systemic lupus erythematosus (SLE). Methods: BIA was conducted of the 
belimumab treatment plus SoC vs SoC alone. Costs of treatments in both groups 
contained following direct medical costs: costs of drugs and administration, costs 
of diagnostic laboratory and instrumental procedure, costs of inpatient and outpa-
tient visits, costs of SLE complications and also adverse event costs. A five-year time 
horizon was used. All costs in both groups were estimated to their present value 
using a 5 % discount rate. Results: Costs of the course of belimumab therapy were 
2,118,449 RUB/ 45,581 EUR for 5 years but the difference in the required budget funds 
between belimumab treatment groups and SoC alone treatment group amounted to 
1,876,965 RUB/ 40,385 EUR for 5 years with a 5 % discount rate. The decrease of the 
difference in the required budget funds between these two groups was due to a lower 
so. Results: Our 1. hypothesis, that the children with normal weight move much, 
than their obese companions, not proven true (p= 0,778). It was the next supposition 
that less are truth with a subject for the students with normal weight they have 
difficulties, than for the obese students. According to the examination, the normal 
one and the obese child with a subject truth in the look of difficulty, we found a 
significant difference (p= 0,015). The third hypothesis, that, in the obese group taller 
the anxious children’s proportion, than the did not grow fat in a group, not proven 
true. The overweight children (n= 46, medium= 109, 76) anxiety with a significantly 
bigger degree was not showed based on the scale the normal one tápláltsági state 
at students (n= 95, medium= 104, 56 dot, p= 0,515). ConClusions: The enrolled 
students showed no significant difference between the observed parameters of the 
overweight and sporting habits.
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objeCtives: Bispectral Index (BIS) monitoring systems monitor spontaneous elec-
troencephalography, track sedative drug effects and help guide anaesthetic admin-
istration. Evidence shows such monitoring enables savings on anaesthesia and 
reduces adverse events compared with monitoring clinical signs only. However, the 
cost-effectiveness of monitors is uncertain. Methods: A cost-effectiveness model 
and budget impact analysis were developed to compare the outcomes of monitor-
ing the depth of anaesthesia with BIS monitors compared with standard clinical 
monitoring. Over a five-year period, the model estimated the incremental cost per 
quality-adjusted life year (QALY) and incremental number of adverse events avoided 
in theatres with anaesthetists using BIS monitors compared with standard care. 
Data values were obtained from peer-reviewed literature. Subgroup analysis was 
conducted for an elderly patient group. Sensitivity analyses explored uncertainty 
in the model. A budget impact model examined the financial impact of adopting 
BIS monitors across the UK. Results: The modelled results showed that using BIS 
monitors dominated clinical observation of signs and use of electrocardiograph 
and other devices, being cost saving by £82 per operation in the adult population, 
whilst improving QALYs by 0.016 per patient. The budget impact analysis showed 
a cumulative saving of over £136 million if theatres in the UK adopted a phased 
increase in monitor use such that 1.35 million surgical procedures were conducted 
using these monitors in five years time. ConClusions: Adopting BIS monitors 
is cost-effective and results in substantial cost savings compared with observing 
clinical signs plus conventional devices only.
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objeCtives: To estimate the costs of drug supply for registered rare diseases (RD) 
patients in Russia in 2013. Methods: The study included two steps: 1) the analysis 
of the current situation with financing of drugs for RD patients in Russia in 2013 
and 2) estimating the unmet needs - necessary weighted average costs (nWAC) for 
a pathogenetic pharmacotherapy of registered patients with RD in the same year. 
Number of registered patients with 24 RD listed in the Government Regulation of 
Russian Federation № 403 from April 26, 2012 was estimated for the studied year. 
Number of registered patients and actual financing has been received from the 
database of regional public health services. The nWAC for expensive pathogenetic 
pharmacotherapy of patients with 24 RD were calculated on the basis of stand-
ards of therapy and experts’ survey results. The current situation with financing 
of RD drugs in Russia in 2013 was compared with unmet needs (nWAC). Results: 
4.4 billion rubles ($125.7 million) were spent from regional budgets in Russia for 
11,173 patients (0.008% from all population of Russia) with 24 RD in 2013. The larg-
est patient group with 3,460 patients was a classic phenylketonuria group. The 
prognostic annual nWAC for pharmacotherapy of the most expensive patient with 
type VI mucopolysaccharidosis were 40.9 million rubles ($1.2 million) per child 
and 71.5 million rubles ($2.0 million) per adult. The nWAC for pharmacotherapy 
of registered patients with 24 RD in 2013 were 15.7 billion rubles ($448.6 million). 
The annual nWAC for pharmacotherapy of the most expensive disease (idiopathic 
thrombocytopenic purpura (Evans syndrome) was estimated as 2.9 billion rubles 
($82.8 million) per group of 2,700 patients. ConClusions: The state financing of 
pharmacotherapy for patients with 24 RD in Russia should be increased approxi-
mately in 3.5 times to fulfill the unmet needs.
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objeCtives: Ultra‐rare disorders (URDs) have been defined by a prevalence of less 
than 1 per 50,000 persons. On a per patient basis, the annual acquisition costs of 
drugs for URDs can be very high, and there have been concerns that expenditures 
for these products might escalate in the future. The goal of this study was therefore 
to provide a budget impact analysis (BIA) of drugs for ultra-rare non-oncological 
diseases in Europe. Methods: The BIA had a time horizon of 10 years (from 2012 
to 2021) and adopted the perspective of all European payers in combination. The 
